Health News: Innovative sécheresse oculaire candidat-médicament 'RCI1001' regains spotlight
'RCI001,' which inhibits Rac1, a cell signaling molecule, is a patented compound that improves the major symptoms of sécheresse oculaire notamment inflammation control, minimal eye irritation, and rapid recovery of épithélium cornéen.
Actuellement, steroid eye drops are used in divers ocular surface diseases notamment traitement de la sécheresse oculaires. Steroid eye drops have excellent effets anti-inflammatoires and provide superior short-term efficacy compared to other medications, but their long-term use is limited in actual clinical settings due to effets secondaires tels que increased pression intraoculaire and cataracts.
In this study, Professeur Kim's team confirmed the inhibitory effects of 'RCI001' on 'Rac1' and 'NLRP3 inflammasome (an inflammation-inducing immune protein).' First, topical treatment with 'RCI001' in an immune-overactivated LPS (Lipopolysaccharide) mouse model confirmed suppression of Rac1 expression and reduction of inflammatoire cytokine expression.
In an alkali-induced mouse eye injury model, 'RCI001' showed faster récupération des lésions cornéennes compared to conventional steroid formulations. De plus, it demonstrated reduced transcription and protein expression of Rac1 signaling molecules and the inflammatoire complex 'NLRP3' in the corneal tissue of this model.